NasdaqGS:SRPTBiotechs
Sarepta Therapeutics (SRPT) Is Down 7.3% After Gene Therapy Lawsuits and Debt Moves – Has The Bull Case Changed?
In recent days, Sarepta Therapeutics faced heightened legal and regulatory pressures as multiple class action lawsuits were filed, alleging false and misleading statements regarding safety risks and patient deaths associated with its ELEVIDYS gene therapy; the company also announced a US$20,000,000 private placement with J. Wood Capital Advisors and refinanced US$700 million of its convertible notes to extend maturities and manage debt.
These developments raise significant questions about...